Glenmark launches Teneligliptin – an advanced Diabetes treatment at significantly affordable cost in India

Glenmark’s Teneligliptin is now available at a cost which is 55% lower than most gliptins in the country

Gliptins globally is fast becoming the most preferred option to manage Type-2 Diabetes

Glenmark’s Teneligliptin is the only gliptin to be manufactured in India from API to formulation. All other Gliptins are presently being imported

The first all-India launch announcement is in Bangalore and Glenmark will commence the roll-out of the product across the state of Karnataka

Bengaluru, August 08, 2015 : Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company today announced the pan-India launch of Teneligliptin in the city of Bengaluru. Teneligliptin, a new third generation oral anti-diabetic agent is used for the management of Type-2 Diabetes mellitus. Globally gliptins is emerging as the preferred line of treatment for managing Type-2 Diabetes. Teneligliptin has been highly effective in decreasing postprandial glucose levels, amount of glucose in the blood after meals, as well as fasting blood glucose levels, with a once-a-day administration .

Glenmark has launched this molecule under two brands – Ziten and Zita Plus at a breakthrough price of Rs. 19.90 per tablet per day treatment. Thus the launch of these two products will lower the daily cost of treatment for a Diabetes patient on gliptin therapy by approximately 55%. Most gliptins are priced at around Rs. 45 per day treatment. This translates into a saving of approximately Rs. 9,000 per year for Diabetes patients with the introduction of Teneligliptin.

Glenmark received approval from DCGI for Teneligliptin after conducting clinical trials on the molecule for over 2 years as per the regulatory requirements. . Glenmark’s Teneligliptin is the only gliptin which is available at lowest cost among all other gliptins being marketed in India while other gliptins are presently being imported.

“Glenmark is proud to be the first player to introduce Teneligliptin an advanced form of treatment for Diabetes at a significantly affordable cost. Through this we will be playing a major role in making anti-diabetics treatment more effective and affordable for millions of patients across the country”; said Sujesh Vasudevan, President & Head – India Business, Glenmark Pharmaceuticals. He added“Gliptins, although a preferred choice of healthcare professionals is out of reach of many patients because of its high price. By offering Teneligliptin at this price, we aspire to bring many more patients in the advanced gliptin therapy fold.”

India is set to be the Diabetes capital of the world. In 2014, 66.8 million cases of Diabetes were reported giving overall national prevalence of 8.63% (IDF 2014). It is estimated that by the year 2035, 110 million patients will be suffering from Diabetes in India (IDF 2014 ). In Bengaluru approximately 26.5% of adult population suffers from diabetes (ASSOCHAM).

Serious long-term diabetes complications include cardiovascular disease, stroke, chronic kidney failure, foot ulcers, and damage to the eyes (WHO Fact sheet January 2015). Presently, only 1 million out of the total Diabetes patient population are estimated to be presently on gliptins. Hence, the launch of Teneligliptin will significantly help millions of patients who could not afford gliptin treatment due to the high cost.

Gliptins have emerged as a highly popular anti-diabetic therapy and are considered the future of anti-diabetic treatment. Gliptins are safe and well tolerated, are weight neutral, have low risk of Hypoglycaemia and are equally efficacious with rare side effects compared to other gliptins (ADA 2014).

Teneligliptin is a selective DPP4 inhibitor that is used in the treatment of Type-2 Diabetes mellitus when satisfactory improvement cannot be achieved through diet and exercise, or in combination of diet and exercise. Without any dose modification it can be safely used in renal and hepatic insufficiencies due to balanced excretion through dual route. Teneligliptin suppresses glucagon release and increases insulin release, subsequently lowering blood-glucose levels by selectively inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates glucagon-like peptide-1 (GLP-1), a hormone excreted from the gastrointestinal track in response to food. Teneligliptin with its potent and sustained action has made it highly effective in lowering each of the blood glucose postprandial levels, as well as fasting blood glucose levels, with once-a-day administration. CCI Newswire